TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group,Placebo Controlled Clinical Trial of the Effects of Tibolone (Org OD-14 1.25mg) on the Incidence of New Vertebral Fractures in Osteoporotic Postmenopausal Women.
Brief Summary: Tibolone 1.25 mg is an effective treatment for the prevention of osteoporosis and is expected to be effective in preventing fractures in osteoporotic women. Tibolone could be more acceptable for long-term use, in particular since it does not induce a regular withdrawal bleed.

The objective of this trial is to compare placebo and tibolone, a steroid with tissue specific activity, in the prevention of spinal fractures in women meeting the WHO criteria for osteoporosis or who have asymptomatic vertebral fractures.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tibolone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tibolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calcium and vitamin D3 supplementation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium and vitamin D3 supplementation; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 3
C: Intervention Type: DRUG; Name: Zoledronic Acid; Assigned to Arm(s): N/A
D: Arm Label: rosiglitazone in addition to background metformin; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Metformin | Arm Label: rosiglitazone in addition to background sulfonylurea; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone, Drug: Sulfonylurea | Arm Label: Sulfonylurea in addition to background metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Arm Label: Metformin in addition to background sulfonylurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulfonylurea, Drug: Metformin | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): rosiglitazone in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background sulfonylurea | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin in addition to background sulfonylurea, Sulfonylurea in addition to background metformin, rosiglitazone in addition to background metformin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to IDDM Regimen in Urban Youth
Brief Summary: The protocol is a randomized clinical trial providing Multisystemic Therapy (MST), an intensive home-based family psychotherapy intervention, to a group of urban adolescents with poorly controlled Type 1 diabetes and their families.


Options:
A: Arm Label: Coping Skills Training + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training, Drug: Amitriptyline | Arm Label: Headache Education + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Headache Education, Drug: Amitriptyline | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills Training + Amitriptyline | Intervention Type: BEHAVIORAL; Name: Headache Education; Assigned to Arm(s): Headache Education + Amitriptyline | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): Coping Skills Training + Amitriptyline, Headache Education + Amitriptyline
B: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy
C: Arm Label: Wait List; Type: OTHER; Interventions: Behavioral: Wait list comparison group | Arm Label: 2 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 2 Family-based problem solving phone sessions | Arm Label: 4 phone sessions; Type: EXPERIMENTAL; Interventions: Behavioral: 4 Family-based problem solving phone intervention sessions | Intervention Type: BEHAVIORAL; Name: 2 Family-based problem solving phone sessions; Assigned to Arm(s): 2 phone sessions | Intervention Type: BEHAVIORAL; Name: 4 Family-based problem solving phone intervention sessions; Assigned to Arm(s): 4 phone sessions | Intervention Type: BEHAVIORAL; Name: Wait list comparison group; Assigned to Arm(s): Wait List
D: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to IDDM Regimen in Urban Youth
Brief Summary: The protocol is a randomized clinical trial providing Multisystemic Therapy (MST), an intensive home-based family psychotherapy intervention, to a group of urban adolescents with poorly controlled Type 1 diabetes and their families.


Options:
A: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone Asthma Program | Intervention Type: BEHAVIORAL; Name: Telephone Asthma Program; Assigned to Arm(s): Intervention
C: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy
D: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to IDDM Regimen in Urban Youth
Brief Summary: The protocol is a randomized clinical trial providing Multisystemic Therapy (MST), an intensive home-based family psychotherapy intervention, to a group of urban adolescents with poorly controlled Type 1 diabetes and their families.


Options:
A: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
B: Arm Label: Multisystemic Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Multisystemic Therapy | Arm Label: Standard Medical Care (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Multisystemic Therapy; Assigned to Arm(s): Multisystemic Therapy
C: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving
D: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community Trial to Assess the Effect of Nutritional Intervention Models on Medical Outcomes Among Obese Type 2 Diabetic Patients
Brief Summary: Obese patients with type 2 diabetes often fail to loose weight and thus do not succeed in improving their sugar and lipid profiles and remain at high risk for diabetes complications

The study enrolled 259 obese diabetic patients attending HMO clinics in central Israel. Over a 6 month period the participants met with a dietitian every fortnight and attended group lectures every 2 months.

The objective of this intervention was to compare three dietary intervention along with close monitoring of the patients by dietitians, regarding blood lipid and sugar balance as well as weight loss. The three diets are the American Diabetes Association (ADA) diet from 2003; a diet containing low glycemic index carbohydrate otherwise similar to the ADA diet; and a low glycemic index diet with more fat than the other 2 diets with high proportion of mono-unsaturated fatty acids.

Patients were individually randomized to receive one of the three diets. Among the measures obtained every 3 months for the first year and every 6 months thereafter are weight, fasting insulin and glucose, glycosylated hemoglobin, blood and urine chemistry profiles and lipid profile.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ADA 2003 | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Glycemic index (LGI) diet | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MUFA diet | Intervention Type: BEHAVIORAL; Name: MUFA diet; Assigned to Arm(s): 3 | Intervention Type: BEHAVIORAL; Name: ADA 2003; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Glycemic index (LGI) diet; Assigned to Arm(s): 2
B: Arm Label: low-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: low-fat diet | Arm Label: moderate-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: moderate-fat diet | Arm Label: high-fat diet; Type: EXPERIMENTAL; Interventions: Behavioral: high-fat diet | Intervention Type: BEHAVIORAL; Name: low-fat diet; Assigned to Arm(s): low-fat diet | Intervention Type: BEHAVIORAL; Name: moderate-fat diet; Assigned to Arm(s): moderate-fat diet | Intervention Type: BEHAVIORAL; Name: high-fat diet; Assigned to Arm(s): high-fat diet
C: Arm Label: Moderately high protein diet; Type: EXPERIMENTAL; Interventions: Behavioral: Moderately high protein diet | Arm Label: Low fat diet; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Low fat diet | Intervention Type: BEHAVIORAL; Name: Moderately high protein diet; Assigned to Arm(s): Moderately high protein diet | Intervention Type: BEHAVIORAL; Name: Low fat diet; Assigned to Arm(s): Low fat diet
D: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo Controlled Trial of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in High-risk Adults in the Critical Care Setting
Brief Summary: Adults admitted to intensive care units are at risk for a variety of complications. Infections due to the fungus called candida are of particular concern. The study will test the possibility that caspofungin, a new therapy for fungal infections, can successfully reduce the rate of candida infections in subjects at risk. It will also test if caspofungin is useful in treating subjects for this disease when diagnosed using a new blood test that is performed twice weekly, permitting earlier diagnosis than current practice standards.


Options:
A: Arm Label: Micafungin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Micafungin | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PLACEBO | Intervention Type: DRUG; Name: Micafungin; Assigned to Arm(s): Micafungin | Intervention Type: DRUG; Name: PLACEBO; Assigned to Arm(s): PLACEBO
B: Arm Label: 1 prophylaxis; Type: ACTIVE_COMPARATOR; Interventions: Drug: Caspofungin | Arm Label: 2 placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Caspofungin; Assigned to Arm(s): 1 prophylaxis | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): 2 placebo
C: Arm Label: Nystatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nystatin | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nystatin | Intervention Type: DRUG; Name: Nystatin; Assigned to Arm(s): Control, Nystatin
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Empiric antifungal therapy based on physician discretion. | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Preemptive Therapy with Anidulafungin | Intervention Type: DRUG; Name: Preemptive Therapy with Anidulafungin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Empiric antifungal therapy based on physician discretion.; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Cardiac Complications in Patients With Cardiac Siderosis During 1 Year Follow-up and the Normal T2* Ranges in LVF, MI and Normal Population.
Brief Summary: The purpose of this study is to provide accurate prognostic data linking cardiac complications to myocardial T2\* values (A measure of iron levels in the heart using MRI)in patients predisposed to heart iron overload.


Options:
A: Arm Label: Starch pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amlodipine | Arm Label: Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine, Starch pill
B: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm
C: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)
D: Arm Label: Thalassemia; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incidence of Cardiac Complications in Patients With Cardiac Siderosis During 1 Year Follow-up and the Normal T2* Ranges in LVF, MI and Normal Population.
Brief Summary: The purpose of this study is to provide accurate prognostic data linking cardiac complications to myocardial T2\* values (A measure of iron levels in the heart using MRI)in patients predisposed to heart iron overload.


Options:
A: Arm Label: Thalassemia; Type: N/A; Interventions: N/A
B: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine
C: Arm Label: SPD602 (16mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Arm Label: SPD602 (32mg); Type: EXPERIMENTAL; Interventions: Drug: SPD602 (FBS0701, SSP-004184) | Intervention Type: DRUG; Name: SPD602 (FBS0701, SSP-004184); Assigned to Arm(s): SPD602 (16mg), SPD602 (32mg)
D: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Brief Summary: This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.


Options:
A: Arm Label: Ferinject (ferric carboxymaltose); Type: EXPERIMENTAL; Interventions: Drug: Ferinject (ferric carboxymaltose) | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care | Intervention Type: DRUG; Name: Ferinject (ferric carboxymaltose); Assigned to Arm(s): Ferinject (ferric carboxymaltose) | Intervention Type: OTHER; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ferinject ® (Ferric carboxymaltose) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9%) | Intervention Type: DRUG; Name: Ferinject ® (Ferric carboxymaltose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal saline (0.9%); Assigned to Arm(s): 2
C: Arm Label: Iron Dextran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron dextran | Arm Label: Iron Sucrose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Iron sucrose | Intervention Type: DRUG; Name: Iron dextran; Assigned to Arm(s): Iron Dextran | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): Iron Sucrose
D: Arm Label: CMS - placebo first; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Venesection, Drug: Iron sucrose, Drug: Normal saline | Arm Label: CMS - iron; Type: EXPERIMENTAL; Interventions: Procedure: Venesection, Drug: Iron sucrose, Drug: Normal saline | Arm Label: SLR - placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Arm Label: SLR - iron; Type: EXPERIMENTAL; Interventions: Drug: Iron sucrose | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): SLR - iron | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): SLR - placebo | Intervention Type: PROCEDURE; Name: Venesection; Assigned to Arm(s): CMS - iron, CMS - placebo first | Intervention Type: DRUG; Name: Iron sucrose; Assigned to Arm(s): CMS - iron, CMS - placebo first | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): CMS - iron, CMS - placebo first

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Brief Summary: This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.


Options:
A: Arm Label: Iron Group; Type: EXPERIMENTAL; Interventions: Drug: Ferrous Sulfate | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Ferrous Sulfate; Assigned to Arm(s): Iron Group | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo Group
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ferinject ® (Ferric carboxymaltose) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9%) | Intervention Type: DRUG; Name: Ferinject ® (Ferric carboxymaltose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal saline (0.9%); Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Iron Sucrose IV 200mg, once a week, for 5 weeks; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ferrous sulfate 200mg PO TID, for 8 weeks; Assigned to Arm(s): N/A
D: Arm Label: Ferric Carboxymaltose (FCM); Type: EXPERIMENTAL; Interventions: Drug: Ferric Carboxymaltose (FCM) | Arm Label: Ferrous Sulfate tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ferrous Sulfate tablets | Intervention Type: DRUG; Name: Ferric Carboxymaltose (FCM); Assigned to Arm(s): Ferric Carboxymaltose (FCM) | Intervention Type: DRUG; Name: Ferrous Sulfate tablets; Assigned to Arm(s): Ferrous Sulfate tablets

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Iron Carboxymaltose (Ferinject®) With Placebo in Patients With Chronic Heart Failure and Iron Deficiency
Brief Summary: This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.


Options:
A: Arm Label: Ferric carboxymaltose; Type: EXPERIMENTAL; Interventions: Drug: Ferric carboxymaltose, Drug: Normal saline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Ferric carboxymaltose; Assigned to Arm(s): Ferric carboxymaltose | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Ferric carboxymaltose, Placebo
B: Arm Label: IV trivalent saccharose hydroxide ferrous; Type: EXPERIMENTAL; Interventions: Drug: IV trivalent saccharose hydroxide ferrous | Arm Label: Oral ferrous fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ferrous fumarate | Arm Label: Oral and intravenous Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Oral and intravenous Placebo | Intervention Type: DRUG; Name: IV trivalent saccharose hydroxide ferrous; Assigned to Arm(s): IV trivalent saccharose hydroxide ferrous | Intervention Type: DRUG; Name: Oral ferrous fumarate; Assigned to Arm(s): Oral ferrous fumarate | Intervention Type: DRUG; Name: Oral and intravenous Placebo; Assigned to Arm(s): Oral and intravenous Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Ferinject ® (Ferric carboxymaltose) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline (0.9%) | Intervention Type: DRUG; Name: Ferinject ® (Ferric carboxymaltose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Normal saline (0.9%); Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Venofer (intravenous iron sucrose); Assigned to Arm(s): N/A

Answer: C